The SAQ is the only severe asthma–specific health-related quality of life (HRQoL) questionnaire for use in adults. For access, licensing, translations, and conditions of use, please visit the official SAQ page on ePROVIDE
- Used by clinicians, researchers and pharmaceutical companies to assess treatment burden and response to biologic therapies.
- Sensitive to change from as early as 4–8 weeks.
- Included in the Core Outcome Measures Set for Severe Asthma (COMSA) and the CONFiRM composite response score.
- Structured around three subscales — MyLife, MyMind, MyBody — covering the physical, psychological and social impact of severe asthma.
Frequently Asked Questions (FAQ) (click to expand)
The SAQ is the only severe asthma–specific health-related quality of life (HRQoL) questionnaire for use in adults. It was developed with patients and is used to measure treatment burden and response to therapy.
The SAQ was developed by a multi-disciplinary team of respiratory specialists, researchers and psychologists based at the University of Plymouth. See the full team→
Yes — the SAQ was co-created with patients and has undergone rigorous statistical validation, including calculation of the questionnaires Minimum Clinically Important Difference (MCID) See the full validation evidence→
The SAQ is structured around three subscales — MyLife, MyMind, MyBody, capturing the physical, psychological and social impact of severe asthma on a patient’s quality of life.
Yes — full detail on COMSA, CONFiRM and biologic response is on the Validation page →
Licensing, access and translations are managed exclusively through Mapi Research Trust. Visit the official SAQ page on ePROVIDE to request access.
Yes, the SAQ has been translated into multiple languages. See available translations →
You can find information about the severe asthma research programme at the University of Plymouth here:
